Journal List > Ann Clin Neurophysiol > v.21(1) > 1121228

Kang, Kim, and Ko: Prognosis of patients with postural tachycardia syndrome: a follow-up study

Abstract

Background

Postural tachycardia syndrome (POTS) refers to the presence of orthostatic intolerance symptoms associated with a heart rate increment of greater than 30 beats/min, usually up to 120 beats/min, on head-up tilt test. Symptoms related to POTS are usually lightheadedness, palpitations and tremor, but syncope can also occur. The pathophysiology of POTS is heterogeneous and its prognosis is uncertain.

Methods

We prospectively evaluated patients who met the criteria for POTS, at baseline and follow-up, using composite autonomic symptom scores and autonomic tests to assess the autonomic function. We compared the clinical and autonomic test results between baseline and follow-up.

Results

Sixty-eight patients met the inclusion criteria for POTS and forty-five patients were ultimately followed up for at least 1 year after baseline. The patients were predominantly young females (84%), with a mean age of 21 years. Most patients showed improved orthostatic symptoms and more than a quarter of patients had no longer met the criteria for POTS at follow-up.

Conclusions

Most patients had a benign outcome in that they could resume their daily activities without great limitations. Our results demonstrated a relatively favorable prognosis in most patients with POTS.

References

1. Low PA, Opfer-Gehrking TL, Textor SC, Benarroch EE, Shen WK, Schondorf R, et al. Postural tachycardia syndrome (POTS). Neurology. 1995; 45(4 Suppl 5):S19–S25.
2. Carew S, Connor MO, Cooke J, Conway R, Sheehy C, Costelloe A, et al. A review of postural orthostatic tachycardia syndrome. Europace. 2009; 11:18–25.
crossref
3. Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vernino S, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc. 2007; 82:308–313.
crossref
4. Stewart JM. Chronic orthostatic intolerance and the postural tachycardia syndrome (POTS). J Pediatr. 2004; 145:725–730.
crossref
5. Grubb BP, Kanjwal Y, Kosinski DJ. The postural tachycardia syndrome: a concise guide to diagnosis and management. J Cardiovasc Electrophysiol. 2006; 17:108–112.
crossref
6. Sandroni P, Opfer-Gehrking TL, McPhee BR, Low PA. Postural tachycardia syndrome: clinical features and follow-up study. Mayo Clin Proc. 1999; 74:1106–1110.
crossref
7. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc. 2012; 87:1196–1201.
crossref
8. Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M, et al. The neuropathic postural tachycardia syndrome. N Engl J Med. 2000; 343:1008–1014.
crossref
9. Furlan R, Jacob G, Snell M, Robertson D, Porta A, Harris P, et al. Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation. 1998; 98:154–159.
10. Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne DW, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 2005; 111:1574–1582.
crossref
11. Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res. 2000; 10:293–299.
crossref
12. Low PA, Sandroni P, Joyner MJ, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2009; 20:352–358.
crossref
13. Sousa A, Lebreiro A, Freitas J, Maciel MJ. Long-term follow-up of patients with postural tachycardia syndrome. Clin Auton Res. 2012; 22:151–153.
crossref
14. Kimpinski K, Figueroa JJ, Singer W, Sletten DM, lodice V, Sandroni P, et al. A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc. 2012; 87:746–752.
crossref

Table 1.
Clinical characteristics of patients with POTS
Feature Finding patient
Age (years) 21.2 ± 9.8 68 (100)
Sex    
 Female/male   57 (84)/11 (16)
Symptom duration (months) 13.1 ± 10.7 68 (100)
Symptom onset    
 Acute (<1 month)   23 (33)
 Subacute (1–3 months)   18 (26)
 Insidious (>3 months)   27 (41)
Preceding events    
 Upper respiratory infection   3 (4)
 Exercise   5 (8)
 Emotional stress   3 (4)
 Heat exposure   2 (3)
 Overeating   2 (3)
 Unknown   53 (78)
Body mass index (kg/m2) 20.8 ± 6.3 68
 <18.5   10
 18.5–24.9   49
 25–29.9   6
 30–34.9   3

Values are presented as mean ± standard deviation or number (%) unless otherwise indicated.

Table 2.
COMPASS-31 scores at baseline and follow-up
COMPASS-31 symptoms Baseline COM-pASS-31
Follow-up COM-pASS-31
p-value
Score Score
Orthostatic intolerance 12.6 ± 11.8 6.7 ± 5.8 0.01
Vasomotor 1.6 ± 2.1 1.5 ± 1.3 0.54
Secremotor 5.4 ± 6.9 5.4 ± 3.5 0.99
Gastrointestinal 6.6 ± 5.4 5.0 ± 3.9 0.39
Bladder 1.1 ± 1.6 1.0 ± 1.8 0.86
Pupillomotor 1.7 ± 1.4 1.5 ± 1.1 0.71
Total score 30.2 ± 23.2 21.4 ± 17.1 0.04

Values are presented as mean ± standard deviation.

COMPASS, composite autonomic symptom score.

table 3.
Autonomic dysfunction on clinical autonomic testing at baseline and follow-up
Test score patients
p-value
Baseline (n = 68) Follow-up (n = 45)
CASS (cardiovagal)     0.97
 0 61 (91) 41 (92)  
 1 4 (5) 2 (4)  
 ≥2 3 (4) 2 (4)  
CASS (adrenergic)     0.94
 0 56 (82) 36 (80)  
 1 8 (11) 6 (13)  
 ≥2 4 (7) 3 (7)  
CASS (sudomotor)     0.89
 0 46 (67) 31 (69)  
 1 15 (22) 9 (20)  
 ≥2 7 (11) 5 (11)  
CASS (total)     0.24
 0 42 (62) 30 (68)  
 1 8 (12) 7 (15)  
 2 10 (15) 5 (11)  
 3 5 (8) 2 (4)  
 4 2 (2) 1 (2)  
 6 1 (1) 0 (0)  

Values are presented as number (%).

CASS, composite autonomic severity score.

TOOLS
Similar articles